Status:

COMPLETED

Cardiac Resynchronisation Therapy and AV Nodal Ablation Trial in Atrial Fibrillation Patients (CAAN-AF)

Lead Sponsor:

University of Adelaide

Collaborating Sponsors:

Medtronic

Abbott Medical Devices

Conditions:

Heart Failure

Atrial Fibrillation

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Cardiac resynchronization therapy (CRT) is a treatment for heart failure in patients who also suffer from ventricular dyssynchrony, a form of uncoordinated contraction of the ventricle (lower pumping ...

Detailed Description

Background: Cardiac Resynchronization Therapy (CRT) is an established treatment in heart failure (HF) patients with ventricular dyssynchrony who remain in sinus rhythm. Available clinical data has sho...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years old
  • Persistent (≥ 1 month) or permanent atrial fibrillation. Persistent AF will be where obtaining and maintaining sinus rhythm is deemed either not worthwhile, or to be ineffective in the long term, or where both the patient and physician accept the presence of AF, where rhythm control intervention is, by definition no longer pursued. Permanent AF is defined as atrial fibrillation where sinus rhythm cannot be restored.
  • NYHA class II , III or ambulatory class IV heart failure
  • Left Ventricular Ejection Fraction (LVEF) ≤ 35% by objective criteria such as echocardiography, or cardiac MRI
  • QRS duration on 12-lead ECG ≥ 120ms
  • Able and willing to comply with all pre-, post- and follow-up testing and requirements.

Exclusion

  • age \< 18 years
  • pregnancy
  • previous AV nodal ablation
  • Second or third degree AV block
  • Inability to provide informed consent
  • life expectancy less than 24 months due to co-morbid illness other than heart failure erg cancer, end-stage renal disease, liver failure
  • Paroxysmal Atrial Fibrillation that self terminates within 7 days

Key Trial Info

Start Date :

March 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 31 2020

Estimated Enrollment :

145 Patients enrolled

Trial Details

Trial ID

NCT01522898

Start Date

March 1 2013

End Date

August 31 2020

Last Update

November 13 2020

Active Locations (33)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 9 (33 locations)

1

Canberra Hospital

Canberra, Australian Capital Territory, Australia, 2605

2

Concord Hospital

Concord, New South Wales, Australia

3

John Hunter Hospital

New Lambton, New South Wales, Australia, 2305

4

Prince of Wales Hospital

Randwick, New South Wales, Australia, 2031